PicMii Groups

Join groups. Create groups. Exchange knowledge.

Clear
2020 Biolabs
  • Public Group

  • Over $12M raised from previous crowdfunding rounds!

    Highlights:

    1. 1. 20/20 Biolabs develops and commercializes AI powered lab tests for the early detection and prevention of cancers and chronic diseases.
    2. 2. We are currently a leader in the Multi-Cancer Early Detection (MCED) market.  MCEDs are expected to be part of routine screenings over the next 5 years likely becoming a multi-billion market in the U.S..
    3. 3. Sales were approximately $1.8 million in 2024, a 23% increase over 2023.
    4. 4. Among the top performers in a 2024 NCI study comparing the performance of dozens of MCEDs .
    5. 5. New longevity blood test to be launched in the 2nd Quarter of this year.
    6. 6. Ranked #134 on 2023 Inc. 5000 list of the “Fastest Growing Companies in America” (#1 in Maryland).
    7. 7. Utilize technology from Abbott Diagnostics and Roche Diagnostics for our multi-cancer and longevity blood tests .
    8. 8. Giant Food, the largest supermarket chain in the Washington, D.C. region, is now promoting our MCED and making blood collections available at their pharmacies
    9. 9. Multiple issued or allowed patents in the U.S. and East Asia (available in Downloads section).
    10. 10. Engaged Maxim Group for a direct listing on the NASDAQ and reserved ticker symbols "TTBL" and "AIDX" from NASDAQ.
    Hundreds of companies are currently providing investors with a chance to buy their stock through equity crowdfunding portals like this one but very few are providing their investors with a near-term pathway to sell those shares when they are ready to do so.  20/20 Biolabs officially engaged Maxim Group, a leading firm on Wall Street for facilitating direct listings of crowdfunded companies, for a direct listing on the NASDAQ and reserved the ticker symbols "TTBL" and "AIDX" from NASDAQ.  We are so confident of our plan to become a public company in the near term that if we fail to do so the notes will mature and we will be required to repay your investment plus interest in accordance with the notes (See financing terms below).

    One of the first clinical labs to enter the fast-growing Multi-Cancer Early Detection (MCED) market, we feature a high quality, affordable blood test that outperforms other competitive technologies.

    The survival rate for many types of cancer significantly improves when treatment is started early, following detection at early stages before the cancer has spread to distant organs. Unfortunately, screening is common for only a small number of tumor types (breast, colon, prostate, cervix) but not for many deadly cancers such as those of the lung, liver, pancreas, and ovaries. Since cancer does not discriminate by income or region, we believe that making tests affordable and accessible is as important as making them accurate.  Simply put, new and innovative cancer tests should be made affordable and available to everyone who is at risk for developing this dreaded disease. Leading global venture funds have invested in 20/20 Biolabs (formerly 20/20 GeneSystems)—now it’s your opportunity to join them. Our mission is to make blood tests that aid in the early detection of cancer available to every adult through offering tests that are better, more affordable, and easier to access than anything else on the market.  We make these tests available to everyone so we can help people detect and treat cancers early, ultimately leading to better cancer outcomes and saving lives. We accomplish this mission by using AI and real-world data to improve upon well established and widely used biomarkers like CEA, AFP, and PSA.  This allows us to keep the costs of running our tests low because our reagents are readily available and commonly used around the world.  The data from these tests can then easily be plugged into our state-of-the-art algorithms to improve their accuracy and provide personalized cancer risk assessments. All testing is performed in a tightly regulated CLIA licensed, CAP accredited, high complexity laboratory with an exemplary record of compliance.  Our lab personnel are very experienced running tests in a high throughput environment, and our state-of-the-art laboratory testing instruments enable us to turn results around rapidly. We are committed to further research not only to improve our currently available cancer tests but to add new and innovative tests to our menu in the future. We will use the same spirit of innovation that drove us in the journey to OneTest Premium in order to continue to enhance our cancer offerings and soon launch new cutting-edge tests including capillary blood collection techniques and tests that aid in healthy aging and longevity.
Sirocco Energy
  • Public Group
  • Sirocco Energy is redefining wind power for businesses in suburban areas, where traditional renewables often fail to provide consistent and cost-effective solutions. We place economic benefit at the forefront by developing technology that delivers effective wind power without relying on additional subsidies, slashing electricity costs for businesses by up to 4 times. Our patented turbines offer a stable, eco-friendly, safe, and economically viable alternative to grid power, solar panels, diesel generators, and other energy sources—providing a sustainable, long-term competitive advantage in a market often dependent on government incentives. With $1M+ raised, a strong advisory board, and backing from the EBRD, we have dedicated seven years to research, development, and market validation to build a product that perfectly fits market needs. With turbine production projected to launch at the end of 2025, confirmed orders of $10 million for 2026, and with the application of a standard market multiplier for the energy sector of 5-7, there is the potential that we could see our valuation climb to between $50 and $70 million within just one year. Furthermore, our roadmap includes launching 100 kW turbines in 2027 and scaling up to 500 kW and 1 MW units in 2028, ensuring robust growth and scalable market expansion. Early investors have a unique opportunity to potentially capture significant value as we work to transform the energy market.
JOGO Health
  • Public Group
Yarnhub
  • Public Group

  • Highlights:

    • • A company producing 3D animated films that reach 35 million views per month on YouTube alone — and growing
    • • A hub for passionate gamers and history enthusiasts
    • • We are uniquely positioned to make the game our community demands
    • • Experienced founders bringing media and games together
    • • Recruited talent from Electronic Arts, Sony and Wargaming
    • • Invest in a growing game studio and Yarnhub’s back catalog, extensive assets, and future video business.

    A leader in cinematic military history

    Founded in 2021, Yarnhub is an animation company producing military history animations. Films are long format, high quality 3D videos, narrating historical tales of bravery, brotherhood and heroes.

    Yarnhub Reach

    The community’s largest audiences are in the USA and Japan, followed by major European countries. Other demographic statistics are:          • 45% Smart TV, 35% Mobile, 20% PC          • 90% Male          • Age evenly distributed

    Yarnhub Revenue

    2025 & 2026 figures are projected ads revenue only.

    By running ads in long format 3D animation films, Yarnhub is generating revenue that has, so far, been fully reinvested into producing higher quality content for its community. The ads revenue alone has seen exponential growth as a result of this increased quality.

    Next steps for explosive growth

    There is no shortage of interest, every film produced receives millions of views and contributes to strengthening the engagement and the business growth. As the Yarnhub community is primarily made of gamers, 90% of its integration revenue comes from gaming ads featured as interstitials. The 3D animated films are produced using the mainstream game engine: Unreal Engine 5. Yarnhub’s extensive library of 3D models and environments, lovingly handcrafted by the team, is just one step away from being integrated into games. The Yarnhub community is extremely vocal in asking Yarnhub to produce a game. In the video comment section, common questions such as: “Is this a game? Where can I play this game?” demonstrates the eagerness of the community to see the company making games. 
Finance Investors
  • Public Group
  • Industries

  • Join a group of investors that focus specifically on finance related companies/investments. These companies have one focus: money. Whether it is insurance, real estate, or money management, these companies are constantly dealing with money.

Technology Investors
  • Public Group
  • Industries
  • Join a group of investors that focus specifically on technology related companies/investments. These companies aim to push the world forward with new innovative products in engineering and software. From apps to robotics, companies in technology are pushing the limits every day of what is possible.
Hospitality Investors
  • Public Group
  • Industries
  • Join a group of investors that focus specifically on hospitality related companies/investments. These companies can range from hotels to restaurants and much more!
Consumer Goods Investors
  • Public Group
  • Industries
  • Join a group of investors that focus specifically on consumer goods companies/investments. These companies develop products that people use every day, such as clothing, food, cars, and much more!
Healthcare Investors
  • Public Group
  • Industries
  • Join a group of investors that focus specifically on healthcare related companies/investments. These companies can range from administering services to developing medicine or healthcare supplies.